Hemcheck Sweden AB has signed an agreement with Capio S:t Göran’s hospital regarding delivery of readers and one-time disposables (v-Test) for usage at the emergency department. After the successful clinical study that was performed at the emergency department earlier in the year, Capio S:t Göran has decided to resume the usage of the solution in the beginning of January 2021. The goal is to evaluate Hemcheck’s solution at a larger scale and to reduce the frequency of hemolyzed blood samples reaching the central laboratory from the emergency department, thereby improving for patients, staff and the hospital. The agreement will approximately imply revenues of ca 100 000 SEK per month.

–The agreement is very important for several reasons and a very good proof of the attractiveness of our solution. It will imply the first broader usage of our solution in an emergency department to handle the issue of hemolyzed blood samples. We very much look forward to continue cooperating with Capio S:t Göran, which has a very good and strong focus on quality, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Capio S:t Göran’s Hospital

Capio S:t Göran’s Hospital is an emergency hospital for adult patients, located at Kungsholmen in Stockholm. The hospital is Stockholm’s most centrally located emergency hospital and one of the country’s largest in terms of the number of emergency patients. In 2019, there were more than 100,000 visits to the emergency care unit. Capio S:t Göran’s Hospital is part of Capio, which in turn is part of Ramsay Générale de Santé, a leading European healthcare provider operating 235 hospitals around the world.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on December 30, 2020 at 16.00